SOURCE: Kinexum

March 24, 2008 09:43 ET

Kinexum Metabolics, Inc. Announces Peter Damsbo, M.D. Joins Clinical Development Team for INGAP Peptide

INGAP Peptide to Begin Clinical Trial in Type 1 Diabetes Patients

WASHINGTON, DC--(Marketwire - March 24, 2008) - Kinexum Metabolics, Inc. (KMI) announced Peter Damsbo, M.D. has joined the clinical development team that is designing human trials for INGAP Peptide which are scheduled to begin in 2008. Dr. Damsbo was formerly Vice President, Clinical Drug Development for diabetes and growth hormones at Novo Nordisk. He joins a distinguished team of advisors and diabetes experts to advance the development of INGAP Peptide for the treatment of Type 1 diabetes and insulin-dependent Type 2 diabetes patients.

"We are very pleased to have Dr. Damsbo, a world-class metabolic drug-developer, join our team," stated Dr. Alexander Fleming, founder of Kinexum. "Major unmet clinical need continues among people with Type 1 diabetes and insulin-dependent Type 2 diabetes. INGAP Peptide is a novel approach for regeneration of islet cells which secrete insulin and other important metabolic hormones. Data from the phase 2 trials already suggest the promise of INGAP, and Peter will play a key role in helping INGAP to and through phase 3."

INGAP Development and New Clinical Trial Design

"The encouraging results from previous 3 month INGAP studies in both Type 1 and insulin-dependent Type 2 patients have taught us much about optimizing dose regimen and study design in future trials. We will also benefit from the guidance on diabetes drugs just released by FDA. FDA's advice on Type 1 therapies now is in line with the international expert consensus that Zan Fleming helped to achieve. INGAP Peptide development will greatly benefit from these advances," stated Dr. Damsbo. KMI is about to start a clinical trial, which will evaluate a refined formulation and delivery regimen. An additional trial for combining INGAP with DiaKine Therapeutics' immune modulator, Lisofylline, is now being planned based on the results of a study in the NOD mouse model for T1 diabetes conducted by Dr. Jerry Nadler, University of Virginia. "Combining INGAP with immune modulation will soon be ready for testing in human trials," stated Dr. Fleming. "The design of these trials will benefit from the animal studies that showed an unprecedented 70% remission rate in a model of well established T1 diabetes." These data are set to be presented by Dr. Nadler at the Keystone Symposia in April. "Combination therapy is an obvious but neglected approach for Type 1 diabetes. I look forward to being a part of these ground breaking efforts and the collaboration of KMI and DiaKine," added Dr. Damsbo.

About Kinexum Metabolics, Inc.

Kinexum Metabolics, Inc. is a biopharmaceutical company focused on the development of therapies for the treatment of Type 1 and Type 2 diabetes and other metabolic conditions.

Contact Information

  • Investor Contact:
    Lisa Jansa
    Office: 952-898-5814
    lisajansa@kinexum.com

    Media Contact:
    Zoe Heineman Myers
    Office: 202-415-6547